Lilly Ajax Therapeutics Acquisition: A New Frontier in Myeloproliferative Neoplasm Care
Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
